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Aim: To monitor the adverse drug reactions (ADRs) caused by antihypertensive medicines prescribed in a university
teaching hospital.
Methods: The present work was an open, non-comparative, observational study conducted on hypertensive
patients attending the Medicine OPD of Majeedia Hospital, Jamia Hamdard, New Delhi, India by conducting patient
interviews and recording the data on ADR monitoring form as recommended by Central Drugs Standard Control
Organization (CDSCO), Government of India.
Results: A total of 21 adverse drug reactions were observed in 192 hypertensive patients. Incidence of adverse
drug reactions was found to be higher in patients more than 40 years in age, and females experienced more ADRs
(n = 14, 7.29%) than males, 7 (3.64%). Combination therapy was associated with more number of adverse drug
reactions (66.7%) as against monotherapy (33.3%). Calcium channel blockers were found to be the most frequently
associated drugs with adverse drug reactions (n = 7), followed by diuretics (n = 5), and β-blockers
(n = 4). Among individual drugs, amlodipine was found to be the commonest drug associated with adverse drug
reactions (n = 7), followed by torasemide (n = 3). Adverse drug reactions associated with central nervous system
were found to be the most frequent (42.8%) followed by musculo-skeletal complaints (23.8%) and gastro-intestinal
disorders (14.3%).
Conclusions: The present pharmacovigilance study represents the adverse drug reaction profile of the
antihypertensive medicines prescribed in our university teaching hospital. The above findings would be useful for
physicians in rational prescribing. Calcium channel blockers were found to be the most frequently associated drugs
with adverse drug reactions.
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Adverse drug reactions have been creating headlines
over the last forty years since the thalidomide tragedy.
International attention to patient safety has been grow-
ing significantly since the publication of the US Institute
of Medicine report “To err is human: building a safer
health system” [1-3]). There is no standard definition of
an adverse drug reaction (ADR). Early studies used their
own definitions, which were indistinct and could be* Correspondence: aqilmalik@yahoo.com
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reproduction in any medium, provided the orinterpreted to include intentional and unintentional
overdose, as well as some administration errors [4,5].
According to World Health Organization (WHO) “An
adverse drug reaction (ADR) is any response to a drug
which is noxious and unintended and occurs at doses
normally used in man for prophylaxis, diagnosis or ther-
apy of disease or the modification of physiological func-
tion” [6]. Food and Drug Administration (FDA) defines
a serious adverse event as one in which the patient out-
come is death, or life threatening, hospitalization, dis-
ability, congenital anomaly or required intervention to
prevent permanent impairment or damage [7]. ADRs are
a major universal problem and are one of the leadingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Frequency of different age groups in ADR and
non ADR hypertensive patients
Age groups (years) Patient with ADRs Patients without ADRs Total
Male Female Male Female
21–30 0 0 12 3 15
31–40 1 0 19 28 48
41–50 1 5 10 33 49
51–60 0 2 23 13 38
61–70 1 0 11 13 25
71–80 2 1 5 7 15
81–90 0 0 2 0 2
Total 5 8 82 97 192
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globally. The incidence of ADR varies with studies. A
published meta-analysis of the incidence of adverse drug
reactions (ADRs) in hospitalized patients concluded that
ADRs rank as the fourth to sixth leading cause of death
in the United States and the overall incidence of serious
ADR accounted for 6.7% of hospitalized patients [8].
According to a study carried out at a private tertiary care
hospital in South India, the incidence of ADRs was
found to be 1.8%, out of which 12% of suspected ADRs
were severe and 49% ADRs were moderate in severity
[9]. A study by Arulmani et al. in India carried out in a
secondary care hospital reported an overall 9.8% inci-
dence of ADRs, of which 3.4% of ADRs were associated
with hospital admissions [10]. Another study carried out
in a tertiary care referral center in South India showed
that admissions due to ADRs accounted for 0.7% of total
admissions and deaths due to ADRs accounted for 1.8%
of total ADRs [11]. Monitoring of ADRs is an ongoing,
ceaseless, and continuing process. Though ADR moni-
toring is still in its infancy in India, this is likely to ex-
pand in the times to come. As the newer drugs are
striking the Indian market, the need for ADR monitoring
is growing more than ever before. Therefore, monitoring
of the adverse effects particularly those of serious nature
is obligatory [12]. It is important to remember that most
ADRs would subside once the offending agent is discon-
tinued or dosage reduced; however, many result in per-
manent damage. Therefore, it is important to motivate
healthcare providers to understand their role and re-
sponsibility in the detection, management, documenta-
tion, and reporting of ADRs, and all essential activities
for optimizing patient safety. The objective of this study
was to monitor the ADRs caused by antihypertensive
medicines prescribed in our university teaching
hospitals.
Methods
The present work was an open, non-comparative, obser-
vational study to reports incidence of ADRs due to anti-
hypertensive medicines at our university teaching
hospital. The study protocol was assessed and approved
by Jamia Hamdard Institutional Review Board (Approval
letter No. JHIRB 07/07, February 15, 2007). The study
was conducted in patients attending the Medicine out-
patient department (OPD) of Majeedia Hospital, a 150
bedded teaching hospital of Jamia Hamdard, New Delhi,
India by conducting patient interviews after their
informed consent was obtained and recording the data
on ADR monitoring form as recommended by Central
Drugs Standard Control Organization (CDSCO), Gov-
ernment of India (http://cdsco.nic.in/adr3.pdf ). The in-
formation collected includes patient information (initials,
age, sex, height, weight), suspected adverse event (briefdescription of the reaction, onset date/stop date of occur-
rence of events, outcomes of events , treatment receive),
suspected medication (name, indication, start date/stop
date, dose, frequency, route of administration), Medical
history (past/present), concomitant medication, relevant
test /laboratory data, other relevant history including
pre-existing medical conditions. All hypertensive patients
irrespective of age and sex and patients treated with at
least one antihypertensive agent were included in the
study. Patients who were not treated with antihyperten-
sive agents, all the mentally retarded and unconscious
patients (patients depending on other people for medica-
tion administration) and drug addicts were excluded
from the study. All the data were kept confidential. The
study was carried out during the period of February 2007
to May 2007 (4 months) by a registered pharmacist
attending the medicine OPD on a daily basis. Study was
conducted on 192 eligible patients at Majeedia Hospital
who were willing to participate. Furthermore, some
patients (n = 13) presenting with ADRs were observed
for changes in biochemical parameters based on patho-
logical lab reports.
The estimation of the probability that a drug caused
an adverse clinical event is usually based on clinical
judgment. For this study, the Naranjo’s scale which cate-
gorizes the causality relationship into definite, probable,
possible or unlikely was used for the assessment of the
exact nature of ADR [13].
Results
During the study period, a total of 192 hypertensive
patients visited Majeedia Hospital. Among the 192-
hypertensive patients 87 (45.4%) were males and 105
(54.6%) were females. A total of 21 ADRs were observed
in 13 out of 192 hypertensive patients. Among the 13
patients reported with ADRs 8 (4.1%) patients were fe-
male and 5 (2.6%) were male (Table 1).
Females experienced more ADRs (n = 14, 7.29%) than
males, (n = 7, 3.64%). The most vulnerable age group
















Sedation 01 (1.47%) Symptomatic
treatment
Pedal edema 01 (1.47%) Symptomatic
treatment









Dizziness 01 (5.55%) No change in
treatment
Total 03 (16.66%)







Grand Total 05 (18.51%)
ACE Inhibitors
Ramipril (33) Dry cough 02 (6.06%) Dechallenge
Total 02 (6.06%)
Angiotensine Receptor Blockers
Telmisartan (17) Dizziness 01 (5.88%) No change in
treatment
Losartan (22) Dizziness 01 (4.54%) No change in
treatment




Atenolol (34) Bradycardia 01 (2.94%) No change in
treatment
Metoprolol (12) Headache 01 (8.33%) No change in
treatment
Propranolol (20) Insomnia 01 (5.00%) Dechallenge
Depression 01 (5.00%) Dechallenge
Total 04 (6.06%)
*The percentage of ADRs was calculated from no of prescriptions of suspected
drug.
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by 71–80 years (n = 3), 51–60 years (n = 2), 31–40 years
and 61–70 years (n = 1 each). No ADR was observed in
the age group of 21–30 years and 81–90 years.
Out of 192 patients, 87 (45.3%) were receiving mono-
therapy and 105 (54.7%) were receiving multiple drug
therapy. A significant difference in number of ADRs was
observed in patients receiving monotherapy (33.3%) than
those on combination therapy (66.7%). Calcium channel
blockers (CCBs) was found to be the commonest thera-
peutic class associated with ADRs (n = 7), followed by
diuretics (n = 5), β-blockers (n = 4), ARBs (n = 3) and
ACE inhibitors (n = 2). Among individual drugs amlodi-
pine was found to be the commonest drug associated
with ADRs (n = 7) with one third of total number of
reported ADRs. The common complaints with the usage
of amlodipine were: abdominal pain, ankle oedema, sed-
ation, pedal oedema, and back pain. Torasemide (a diur-
etic) was the next drug on the list of suspect drugs with
3 (14%) of total number of ADRs with fatigue, visual im-
pairment and dizziness being the adverse effects. Dry
cough was the most frequent ADR observed in our study
with ramipril (Table 2).
On Naranjo’s probability scale more than half (57%) of
the reported ADRs were classified as “possible”, 38% as
“probable” and ~ 5% as “unlikely”. ADRs associated with
CNS (n = 9, 42.8%) were found to be most frequent (e.
g., dizziness, headache, depression etc.) followed by
Musculo-skeletal (n = 5, 23.8%) complaints (e.g., back
pain, fatigue ankle and pedal edema) and gastrointestinal
(n = 3, 14.3%) disorders (e.g., abdominal pain, anorexia),
(Table 3). Majority of ADRs observed in our study were
mild (n = 14, 66.6%), which were well tolerated by the
patients for example, headache, dizziness etc. followed by
moderate (n = 7, 33.3%) ADRs, e.g. insomnia, depression
(propranolol), ankle oedema (amlodipine) etc. The
offending drug was withdrawn (dechallenged) which
reversed the symptoms. None of the ADRs was categor-
ized as severe.
The biochemical parameters of the patients who
experienced ADRs were mostly unperturbed. Only one
patient who presented with ramipril associated dry
cough had elevated Serum glutamate pyruvate trans-
aminase (SGPT) and Serum glutamate oxaloacetate
transaminase (SGOT) levels. The blood sugar levels were
found to be more than the normal values only in
patients with concomitant diabetes mellitus (Table 4).
Discussion
The demographic details of our study population
showed female gender predominance over males, which
was similar to that reported in other studies found in
the literature [10,11,14-18]. This might be due to higher
emotion quotient in females, which makes them more
Table 3 Organ system affected due to ADRs
Organ System No. of ADRs %* of ADRs
Central Nervous System 09 42.8
Musculo-skeletal System 05 23.8
Gastro-intestinal System 03 14.3
Respiratory System 02 9.5
Eye 01 4.8
Cardiovascular System 01 4.8
Total 21 100
*The percentage of ADRs was calculated from total no. of observed ADRs.
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thus enhancing the probability of ADRs. Rational dose
titration may lead to minimization of ADRs in females.
Incidence of ADRs was found to be higher in older
patients i.e., more than 40 years (n = 12) as compared to
younger ones i.e., less than 40 years (n = 1). Compro-
mised organ functions, decreased BMR (basal metabolic
rate), concomitant disease conditions and multiple drug
regimens might be assigned as likely reasons for higher
incidence of ADRs in older patients.
As anticipated, multiple therapies (more than one
drug) were associated with more number of ADRs (67%)
as against monotherapy (33%). Many epidemiological
studies on risk factors for ADRs have shown that
patients on multiple therapies were more likely to de-
velop ADR as compared to patients on monotherapy
[15,19-21]. Multiple therapies need to be discouraged as
these enhance the probability of ADRs due to drug–drug














1 HTN 01 38 M 15 12 121 2
2 HTN 02 50 F 37 27 189 3
3 HTN 03 46 M 27 33 159 7
4 HTN 04 73 M 27 33 290 1
5 HTN 05 47 F 16 12 343 1
6 HTN 06 58 F 40 42 122 3
7 HTN 07 45 F 37 28 180 3
8 HTN 08 45 F 26 29 250 3
9 HTN 09 75 M 34 42 148 1
10 HTN 10 80 F 27 29 130 2
11 HTN 11 63 M 27 38 189 3
12 HTN 12 60 F 30 28 110 2
13 HTN 13 50 F 68 81 107 1
B. Sugar: Blood Sugar, B. Urea: Blood Urea, S. Creatinine: Serum Creatinine, S. Sod
oxaloacetate transaminase, SGPT: Serum glutamate pyruvate transaminase.essential medicines be prescribed in the management of
hypertension.
CCBs were the most frequently associated drugs with
ADRs. This is consistent with the findings of previous
studies [16,22,23]. By contrast β-blockers have also been
reported more significantly associated with ADRs than
other drug categories [15,24] and the physicians consid-
ered discontinuing the treatment more frequently in
patients receiving β-blockers in comparison to other
drugs [15]. Among individual drugs amlodipine was
found to be the commonest drug associated with ADRs.
The common complaints with the usage of amlodipine
were: abdominal pain, ankle oedema, sedation, pedal
oedema, and back pain. Oedema has been reported else-
where as the most common problem with amlodipine
[16] and in other study conducted on 57 patients in Bel-
gium [25]. Also, flushing, dizziness and peripheral
oedema have been mentioned as common complaints
with CCBs in a review [26]. Torasemide (a diuretic) was
associated with fatigue, visual impairment and dizziness
being the adverse effects. Dizziness and headache have
been reported as common side effects associated with
diuretics. These side effects could be related to the fluid
or electrolytes imbalance caused by these medicines
[26]. Dry cough was the most often ADR observed in
our study with ramipril. This is in confirmation of previ-
ous reports with almost 44% of patients experiencing
dry cough on using ACE inhibitors [22,27]. The adverse
effects observed with other medicines were consistent
with their pharmacological profiles.
The effects of ADRs on different organs/systems of










1 0.8 144 4.5 105
2 1.3 144 4.2 106
4 1.8 135 5.1 106
6 0.9 138 4.8 98
5 0.8 139 3.9 102
2 1.0 141 4.4 103
2 1.3 144 4.2 104
8 1.2 140 4.3 100
8 0.9 141 4.5 105
5 1.2 140 4.6 102
0 1.3 140 4.8 104
6 0.9 139 4.3 103
7 1.0 146 4.6 108
ium: Serum Sodium, S. Potassium: Serum Potassium, SGOT: Serum glutamate
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verse drug reactions. The most common systems asso-
ciated with ADRs in our study were the central nervous
system (CNS) followed by musculo-skeletal complaints.
This finding is consistent with previous studies which
have reported CNS manifestation [10,18,23,28]. The
gastrointestinal system has also been reported to be
involved in the majority of ADRs [10,18,23,29]. In our
study, this formed the third largest report on ADRs.
The biochemical parameters of the patients who
experienced ADRs were mostly unperturbed. Only one
patient who presented with ramipril associated dry
cough had elevated SGPT and SGOT levels. As the en-
zymatic levels were altered in an odd patient, it is con-
cluded that the elevated SGPT and SGOT levels might
be due to concomitant disease condition(s) and could
not be attributed to ramipril administration. One patient
receiving torasemide presented with fatigue and visual
impairment along with elevated blood urea and serum
creatinine levels. Again as the above observation was in
merely one patient, the elevated blood urea and serum
creatinine levels could be assigned to other pathological
conditions and might not have been induced by torase-
mide. The blood sugar levels were found to be more
than the normal values only in patients with concomi-
tant diabetes mellitus.
Conclusion
The above study is a part of ongoing pharmacovigilance
program conducted at our university teaching hospital.
During this pharmacovigilance study, calcium channel
blockers were found to be the most frequently associated
drugs with ADRs followed by diuretics, β-blockers, ARBs
and ACE inhibitors. As the present study is related to
ADR profile of antihypertensive agents, it may be helpful
in selection of appropriate medicines for hypertensive
patients, enhancing patient adherence with the therapy
by selecting medicines of lesser ADRs profile, reducing
unnecessary economic burden to the patients due to un-
wanted effects of the therapy.
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